Table 1 Baseline characteristics of the enrolled individuals in the derivation cohort and temporal validation cohort dataset
Characteristics | All patients (n = 10,874) | Derivation cohort (n = 8820) | Temporal validation cohort (n = 2054) |
|---|---|---|---|
YOCRC | 477 (4.4%) | 399 (4.5%) | 78 (3.8%) |
Sociodemographic | |||
Age (y) | 43 (36–48) | 43 (36–48) | 43 (35–47) |
Male, n (%) | 6076 (55.9%) | 4976 (56.4%) | 1100 (53.6%) |
Height (m) | 1.65 (1.60–1.72) | 1.65 (1.60–1.72) | 1.65 (1.59–1.72) |
Weight (kg) | 63 (55–72) | 62.5 (55–72) | 64 (55–74) |
BMI (kg/m²) | 22.49 (20.20–25.06) | 22.49 (20.20–25.04) | 22.51 (20.31–25.06) |
Smoking, n (%) | 705 (6.5%) | 476 (5.4%) | 229 (11.1%) |
Alcohol intake, n (%) | 534 (4.9%) | 357 (4.0%) | 177 (8.6%) |
Family history of CRC, n (%) | 100 (0.9%) | 70 (0.8%) | 30 (1.5%) |
Comorbidity | |||
DM, n (%) | 205 (1.9%) | 178 (2.0%) | 27 (1.3%) |
Hyperlipidemia, n (%) | 194 (1.8%) | 156 (1.8%) | 38 (1.9%) |
Hypertension, n (%) | 580 (5.3%) | 471 (5.3%) | 109 (5.3%) |
Cardiac failure, n (%) | 54 (0.5%) | 40 (0.5%) | 14 (0.7%) |
CKD, n (%) | 18 (0.2%) | 16 (0.2%) | 2 (0.1%) |
History of stroke, n (%) | 34 (0.3%) | 30 (0.3%) | 4 (0.2%) |
Medications | |||
Aspirin, n (%) | 46 (0.4%) | 35 (0.4%) | 11 (0.5%) |
Statin, n (%) | 34 (0.3%) | 25 (0.3%) | 9 (0.4%) |
Symptoms | Â | Â | Â |
Hematochezia, n (%) | 925 (8.5%) | 778 (8.8%) | 147 (7.2%) |
Altered bowel habit, n (%) | 958 (8.8%) | 764 (8.7%) | 194 (9.4%) |
Diarrhoea, n (%) | 658 (6.1%) | 526 (6.0%) | 132 (6.4%) |
Constipation, n (%) | 161 (1.5%) | 131 (1.5%) | 30 (1.5%) |
Abdominal pain, n (%) | 1360 (12.5%) | 1108 (12.6%) | 252 (12.3%) |
Abdominal distension, n (%) | 928 (8.5%) | 710 (8.0%) | 218 (10.6%) |
Abdominal mass, n (%) | 14 (0.1%) | 13 (0.2%) | 1 (0.05%) |
Anorexia, n (%) | 9 (0.1%) | 7 (0.1%) | 2 (0.1%) |
Unexplained weight loss, n (%) | 8 (0.1%) | 7 (0.1%) | 1 (0.05%) |
Laboratory data | |||
WBC, 109/L | 5.80 (4.69–7.10) | 5.79 (4.68–7.11) | 5.84 (4.74–7.10) |
Neutrophils, 109/L | 3.37 (2.58-4.39) | 3.36 (2.56-4.39) | 3.43 (2.63-4.35) |
Lymphocytes, 109/L | 1.66 (1.27–2.08) | 1.66 (1.26–2.07) | 1.69 (1.31–2.10) |
Monocytes, 109/L | 0.44 (0.34–0.56) | 0.43 (0.34–0.56) | 0.45 (0.35–0.56) |
Eosinophiles, 109/L | 0.09 (0.05–0.16) | 0.09 (0.05–0.16) | 0.10 (0.05–0.17) |
PLT, 109/L | 226 (185–273) | 225 (185–272) | 228 (187.75–276) |
Hemoglobin, g/L | 135 (120–150) | 135 (120–149) | 136 (122–150) |
RDW | 0.13 (0.12–0.14) | 0.13 (0.12–0.14) | 0.13 (0.12–0.14) |
MCV, fL | 89.80 (86.60–92.80) | 89.80 (86.60–92.80) | 89.70 (86.70–92.90) |
CRP, mg/L | 0.54 (0.50–5.00) | 0.64 (0.50–5.00) | 0.50 (0.50–3.09) |
ALT, U/L | 19 (13–30) | 19 (13–30) | 19 (13–30) |
AST, U/L | 21 (17–27) | 21 (17–27) | 21 (17–26) |
GGT, mmol/L | 20 (12–35) | 20 (12–36) | 20 (12–34.75) |
TBil, mmol/L | 11.52 (8.57–15.64) | 11.50 (8.56–15.60) | 11.60 (8.61–15.82) |
DBil, mmol/L | 3.40 (2.50–4.70) | 3.40 (2.50–4.60) | 3.40 (2.50–4.80) |
TPO, g/L | 69.20 (65.30–73) | 69.30 (65.40–73.10) | 68.80 (65–72.60) |
Albumin, g/L | 43.80 (41.12–46.05) | 43.80 (41.10–46.00) | 43.80 (41.21–46.10) |
A/G | 1.71 (1.54–1.90) | 1.71 (1.54–1.89) | 1.74 (1.56–1.93) |
ALP, mmol/L | 67 (55–83) | 67 (55–83) | 66.60 (54.58–82.60) |
LDH | 179 (159–207) | 179 (159–208) | 179 (158–206) |
TG, mmol/L | 1.34 (0.91–2.10) | 1.35 (0.92–2.09) | 1.34 (0.90–2.15) |
Total cholesterol, mmol/L | 4.28 (3.72–4.92) | 4.29 (3.72–4.92) | 4.25 (3.71–4.90) |
HDL, mmol/L | 1.12 (0.93–1.36) | 1.12 (0.94–1.36) | 1.12 (0.93–1.35) |
LDL, mmol/L | 2.36 (1.91–2.90) | 2.37 (1.90–2.90) | 2.36 (1.94–2.92) |
ApoA1, g/L | 1.29 (1.15–1.45) | 1.29 (1.15-1.45) | 1.29 (1.16–1.46) |
ApoB, g/L | 0.79 (0.66–0.93) | 0.79 (0.66–0.93) | 0.78 (0.66–0.93) |
Lipoprotein (a), g/L | 102 (48–230) | 103.10 (48.20–238) | 106 (51–234.75) |
Blood glucose, mmol/L | 4.95 (4.54–5.52) | 4.95 (4.56–5.51) | 4.94 (4.48–5.54) |
CEA, ng/mL | 1.09 (0.50–2.27) | 1.10 (0.50–2.31) | 1.04 (0.50–2.11) |
Positive FIT, n (%) | 668 (15.4%) | 560 (15.4%) | 108 (15.6%) |
